Enabling a Comeback in Ion Channel Drug Discovery

Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx looks at Sophion Bioscience, Nanion Technologies, and Xention Discovery, three emerging European firms whose platforms may help return ion channels to the forefront of biotech and pharmaceutical companies' discovery targets.

Ion channels—tiny protein pores in the membranes of each living cell—are the gateways for millions of positively or negatively charged ions that flow in and out of a cell every second, affecting its electrochemical balance and controlling many biological processes. As ion channel functions are intrinsic to basic physiological processes like nerve and muscle activity, pharmaceutically modulating the extent to which ions enter or leave cells has proven very useful and lucrative to drug firms. Ion channel proteins are the second-most targeted class of proteins, behind G-protein coupled receptors (GPCRs), and drugs that modulate ion channels address a set of diseases such as epilepsy, arrhythmia, cystic fibrosis and Type II diabetes, collectively described as channelopathies.

Ion channels aren't just important as drug targets, however. Since certain ion channels may be responsible for unwanted and dangerous...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.